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SUMMARY – Lung cancer as the major cause of cancer mortality worldwide includes several 
histologic subtypes evolving from numerous genetic and epigenetic changes emerging in alveolar, 
bronchiolar and bronchial epithelium. Th e majority of cases are diagnosed in advanced stage (i.e. 
stages IIIB and IV), often with scanty amount of tissue in transbronchial biopsies or cytology speci-
mens. Th e aim of the present study was to investigate the expression of the scaff olding protein neural 
precursor cell expressed, developmentally downregulated 9 (NEDD9) in small biopsies of lung adeno-
carcinoma. Th e expression of NEDD9 was analyzed immunohistochemically in 71 formalin-fi xed and 
paraffi  n-embedded transbronchial biopsy specimens of primary lung adenocarcinoma. Nuclear and 
cytoplasmic NEDD9 expression was detected indicating activation of the epithelial-mesenchymal 
transition process. Direct relationship between the expression of NEDD9 and survival was not 
 demonstrated.
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Introduction
Th e declining incidence rates of lung cancer in 
women in the mid-2000s followed the lung cancer de-
creasing incidence rate in male population in the 1980s 
as a direct result of the anti-smoking campaigns in 
previous decades. However, lung cancer is still the 
leading cause of cancer mortality worldwide1. In 2016, 
lung cancer preceded 14% and 13% of the most com-
mon newly diagnosed malignances in men and wom-
en, respectively, and was the second most common 
malignancy following prostate cancer in men and 
breast cancer in women2. Since cancer cells have to un-
dergo multiple genetic and epigenetic changes pro-
moting multiplied proliferation potential in parallel 
with some degree of resistance to programmed cell 
death during cancer growth, identifi cation of these 
changes has become an ultimate clinical goal in the 
past decade. Due to the continuous increase in the in-
cidence of lung adenocarcinoma in the past decades, 
now it is the most common histologic type of lung 
cancer3.
Neural precursor cell expressed, developmentally 
downregulated 9 (NEDD9) triggers mitotic check-
point, regulates cellular attachment and migration, and 
ciliary resorption, but also apoptosis and anoikis, i.e. 
programmed cell death due to the loss of attachments. 
NEDD9 is involved in the control of cellular diff eren-
tiation, migration and chemotaxis, acting as a scaff old-
ing protein in the complex process of epithelial-mes-
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enchymal transition (EMT)4. NEDD9 has been iden-
tifi ed as an integral part of the complex process of 
metastatic potential acquisition in mammary adeno-
carcinoma, glioblastoma and metastatic melanoma5-7. 
Moreover, some recent data suggested correlation be-
tween NEDD9 expression in resected specimens of 
lung adenocarcinoma and survival8.
However, lung carcinomas are often diagnosed in 
scanty amounts of tissue obtained by transbronchial 
biopsies or in cytology samples in up to 70% of all 
cases, even in the high-resource centers. Th erefore, we 
aimed to investigate the expression of NEDD9 and its 




Out of 90 formalin-fi xed paraffi  n-embedded rou-
tine diagnostic transbronchial biopsies from the ar-
chives of the Institute of Pathology, School of Medi-
cine, University of Zagreb, 71 were eligible for the 
study conducted between January 2002 and December 
2004. Identity protection was in strict accordance with 
the Declaration of Helsinki, 7th revision. Patient sur-
vival was defi ned as the time elapsed from the date of 
tissue collection to the end of the follow-up period or 
the date of death according to the National Cancer 
Registry. Th e samples were stained with hematoxylin 
and eosin and the diagnosis was confi rmed by immu-
nochemistry using TTF-1, CK7 and napsin A panel 
of antibodies for adenocarcinoma confi rmation and 
p63 and CK5/6 antibodies to exclude squamous cell 
carcinoma.
Methods
Immunohistochemistry was performed on 4 μm 
thick sections by standard protocols with primary an-
tibodies including TTF-1 (Novocastra, Great Britain), 
CK7 (Dako, Denmark), napsin A (Novocastra, Great 
Britain), CK5/6 (Dako, Denmark) and p63 (Novocas-
tra, Great Britain).
Th e NEDD9 monoclonal antibody (Abcam, San 
Francisco, CA, USA) was used in 1:400 dilution with 
EnVision kit for visualization. Normal bronchial epi-
thelium present in tumor surroundings was used as 
negative control. Th e ‘hot spot’ was determined by in-
spection on whole specimen at x40 magnifi cation by 
two investigators blinded for the clinicopathologic 
data. Th e immunohistochemical reaction was exam-
ined at x400 magnifi cation.
Th e percentage of NEDD9 positive tumor cells 
was assessed semiquantitatively, as follows: 0-25% of 
positive cells scored 0 or negative; 26%-50% as 1 
(weakly positive); 51%-75% as 2 (mildly positive); and 
more than 75% of positive tumor cells as 3 (strongly 
positive). Positivity was evaluated separately for nuclei 
and cytoplasm. Th e intensity of staining was also 
scored in the range of 0-3 (negative, weakly stained, 
mildly or strongly stained) (Fig. 1).
Statistical analysis
All data analyses were performed using IBM SPSS 
Statistics, version 24.0. Quantitative data distribution 
Fig. 1. (a) Strong nuclear expression of NEDD9 in lung adenocarcinoma (x400); (b) strong cytoplasmic expression 
of NEDD9 in lung adenocarcinoma (x400).
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was analyzed by the Kolmogorov-Smirnov test, corre-
lations between categorical and nominal data were 
analyzed using the χ2-test, and correlations between 
immunoreactivity and survival by Spearman’s coeffi  -
cient of correlation. Survival curves were generated us-
ing the Kaplan-Meier method and the log-rank test 
was performed for survival data analysis. Th e level of 
statistical signifi cance was set at p<0.05.
Results
Seventy-one out of 90 selected transbronchial bi-
opsy samples were eligible for analysis; 8 samples con-
tained insuffi  cient tumor tissue for further analysis, 7 
were pulmonary metastases, immunohistochemically 
confi rmed, and 4 were diagnosed as squamous cell car-
cinomas.
Fifty-fi ve out of 71 lung adenocarcinoma cases 
were male (77.5%). Mean age of all patients was 74.3 
years. Th e patients diagnosed with pulmonary adeno-
carcinoma were part of a larger cohort study and the 
diagnosis was confi rmed by immunohistochemical 
staining for TTF-1, CK7, p63, CK5/6 and napsin A. 
Table 1 shows results of testing for diff erent antibod-
ies, and Table 2 shows diff erent combinations of anti-
bodies found positive in study subjects.
Assessment methods (percentage scale of staining 
intensity and semiquantitative scale) correlated signifi -
cantly (p<0.001) in both nuclei and cytoplasm, with 
Spearman correlation coeffi  cient of 0.905 for nuclei 
and 0.786 for cytoplasm. Because of such high correla-
tion coeffi  cients, suggesting both scales to measure the 
same attribute, only the latter (semiquantitative) 
method will be discussed hereafter. Table 3 shows the 
number and percentage of specimens by the intensity 
of NEDD9 staining of both nucleus and cytoplasm.
Analysis of staining results for the nuclei and cyto-
plasm of our samples revealed an inverse pattern in 
staining intensity between them, i.e. only a small frac-
tion of nuclei stained with intensity of 3 while a simi-
lar small fraction of cytoplasm stained with intensity 
of 0. To overcome this, further grouping of staining 
categories was performed, so that groups 0 and 1 were 
merged, as well as groups 2 and 3. Survival analysis was 
performed on such transformed groups of NEDD9 
staining intensity and results are presented in Table 4 
and Figure 2. Although the level of statistical signifi -
cance was not reached, the results suggested stronger 
NEDD9 staining intensity to correlate with longer 
survival. Th is was true for both nuclei and cytoplasm 
staining intensity, with the eff ect being signifi cantly 
more pronounced in cytoplasm.
Discussion
Th e last decade was characterized by a growing sci-
entifi c interest for the members of the Crk-associated 
substrate (CAS) adaptor protein family, namely 
p130Cas/BCAR1 and NEDD9/HEF1/Cas-L. Al-
though the catalytic function has not yet been demon-
strated for any member of the CAS family, it is clear 
that these proteins serve as hubs for many vital cellular 
processes owing to multiple protein interaction motifs 
on their surfaces. NEDD9 has numerous roles in 
Table 1. Number of specimens positive 
for each of antibodies tested





Napsin A 31 (43.7)
Table 2. Number of specimens positive for diff erent 
antibody combinations
Antibody Positive (+/-)
TTF-1 - + + - - + - + +
CK7 + + + + - - - - +
p63 - - - - - - - - +
CK5/6 - - - - - - - - -
Napsin A - + - + - + + - -
Total 25 24 10 3 3 2 2 1 1
Table 3. Staining intensity for NEDD9 in nuclei 
and cytoplasm of adenocarcinoma specimens
Staining intensity
Number (%) of specimens
Nuclei Cytoplasm
0 30 (42.3) 7 (9.9)
1 10 (14.1) 23 (32.4)
2 27 (38.0) 23 (32.4)
3 4 (5.6) 18 (25.4)
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modulating and controlling normal cell cycle, cellular 
attachment, migration and chemotaxis, and therefore 
has been studied mostly in the context of epithelial-
mesenchymal transition, i.e. cancer growth, invasion 
and metastasis formation. To date, overexpression of 
NEDD9 has been demonstrated in various malignan-
cies. Recently, its positive correlation with lymph node 
metastasis in non-small cell lung carcinoma (NSCLC) 
has been described in a series of 105 resected tumors8. 
However, since the vast majority of lung cancers are 
diagnosed by use of small biopsy and cytology speci-
mens, we aimed to analyze NEDD9 expression and its 
correlation with survival in small biopsy samples of 
lung adenocarcinoma diagnosed according to the lat-
est World Health Organization classifi cation of lung 
tumors9. To our knowledge, our study is the fi rst one 
analyzing NEDD9 expression in transbronchial biop-
sies of lung adenocarcinoma.
In our series of transbronchial biopsies, the diagno-
sis of adenocarcinoma was confi rmed by TTF-1, CK7 
and/or napsin A positive reaction. Of note, napsin A 
stained positive in 8 (11.3%) cases of TTF-1-negative 
tumors, two of which were double-negative for TTF-
1/CK7. Th is fi nding has been reported in recent litera-
allows homo- and heterodimerization of the NEDD9 
molecule and subsequent interaction with downstream 
molecules mediating cellular migration. Also, NEDD9 
concentrates at the mitotic spindle and interacts with 
the centrosome and proteasomal machinery with both 
nuclear and cytoplasmic pools, where its expression 
and activities are closely regulated by rapid turnover12. 
In our study, signifi cant levels of expression were found 
in both nuclear (41/71, 57.7%) and cytoplasmic de-
partments (64/71, 90.1%) of adenocarcinoma cells. 
Th is fi nding is in concordance with the results of an 
earlier study in which Chang et al. investigated 
NEDD9 localization and expression in 60 cases of 
surgically treated lung adenocarcinoma13. It has been 
postulated that NEDD9 serves as a sort of switch 
driving cell migration in the early stages of neoplastic 
transformation and contributes to the invasive proper-
ties14. McLaughlin et al. found that increased expres-
sion of NEDD9 correlated with the transformation 
from breast carcinoma in situ to invasive tumor15. On 
the other hand, NEDD9 expression correlated in-
versely with recurrence-free survival, but also in pa-
tients treated with curative surgery, i.e. earlier stages of 
the disease16. Furthermore, NEDD9 expression was 
Table 4. Mean survival time in months (with 95% 




0 and 1 26.7 (14.3-39.1) 21.0 (8.6-33.4)
2 and 3 35.5 (17.4-53.6) 38.1 (22.2-54.1)
p 0.687 0.199
Fig. 2. Survival time in months based on intensity of NEDD9 staining of nuclei (left) and cytoplasm (right) 
of adenocarcinoma specimens.
ture with napsin A described as a particularly useful 
tool in identifying double-negative (TTF-1/CK7) tu-
mors as adenocarcinoma, since it is persistently nega-
tive in squamous cell carcinoma10,11.
Th e NEDD9 has been shown to concentrate at fo-
cal adhesions in response to binding of various intrin-
sic and extrinsic partner proteins to the SH3-domain 
and highly conserved carboxy-terminal domain that 
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correlated with smoking history, TNM stage and 
lymph node metastasis (but with no apparent correla-
tions with other clinical features), indicating the role 
of NEDD9 in the disease progression17. Recently, 
Miao et al. demonstrated inverse correlation between 
NEDD9 expression and overall survival in patients 
with resectable NSCLC (but interestingly, not with 
the TNM stage)8. In our study, the investigated rela-
tionship between NEDD9 expression and survival did 
not reach statistically signifi cant diff erence. Quite sur-
prisingly, there was a trend towards correlation of 
stronger NEDD9 staining intensity to longer survival. 
Th is was true for both nuclear and cytoplasmic expres-
sion, with the eff ect being signifi cantly more pro-
nounced in cytoplasm. Considering numerous func-
tions of NEDD9 in complex processes of cellular dif-
ferentiation and migration, it is expected that the over-
expression in lung carcinomas is a marker of a higher 
malignant potential. On the other hand, it has been 
demonstrated that expression of NEDD9 over certain 
level inevitably leads to apoptosis18. Furthermore, 
Minn et al. independently demonstrated down-regula-
tion of NEDD9 as part of metastatic signature in 
mammary tumors19. It is plausible to conclude that the 
levels of NEDD9 must be precisely and timely regu-
lated, and the overexpression can be tolerated only in 
tumor cells with extensive prior lesions that enable es-
caping cellular death. It is also possible that elevated 
expression of NEDD9 may indicate better responses 
to therapy16. Pallarès et al. have described unexpected 
discovery of NEDD9 (but not BCAR1) expression as 
an independent prognostic factor of favorable progno-
sis in intermediate-risk acute myeloid leukemia, which 
is in contrast with the previously reported higher ag-
gressiveness in BCR-ABL-dependent acute lympho-
blastic leukemia20.
We demonstrated both nuclear and cytoplasmic 
expression of NEDD9 in transbronchial biopsies of 
lung adenocarcinoma indicating activation of the epi-
thelial-mesenchymal transition process. However, we 
were unable to demonstrate relationship between the 
expression of NEDD9 and survival.
Our study had several limitations; data were ob-
tained on a rather small population, with the possibil-
ity of selection bias, and it was performed on small 
biopsies. It would be of interest to extend our study to 
the resected tumors and correlate these results with 
other clinical parameters (such as TNM stage, tumor 
size, and response to therapy) in a larger group. Taking 
into account the complex functions of NEDD9 and 
precise regulation of numerous diff erent interconnect-
ed signaling networks, more future studies are war-
ranted before targeting NEDD9 as one of the possible 
routes in precision oncology.
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Sažetak
EKSPRESIJA NEDD9 U TRANSBRONHALNIM BIOPTATIMA ADENOKARCINOMA PLUĆA
J. Ostojić, L. Brčić, P. Hrabač i S. Seiwerth
Karcinom pluća objedinjuje zloćudne tumore nastale brojnim genetskim i epigenetskim promjenama epitelnih stanica 
bronha, bronhiola i alveola, i predstavlja najčešći uzrok smrti među malignim bolestima. U većini slučajeva dijagnoza se 
 postavlja u uznapredovalim stadijima bolesti (IIIB. i IV.) iz uzoraka transbronhalnih biopsija ili citoloških materijala. U ovom 
istraživanju ispitana je ekspresija regulatorne bjelančevine nazvane neural precursor cell expressed, developmentally downregula-
ted 9 (NEDD9) u 71 uzorku malih biopsija adenokarcinoma pluća. Utvrđena je izražena ekspresija NEDD9 u jezgri i cito-
plazmi stanica adenokarcinoma, koja ukazuje na aktivaciju epitelno-mezenhimne tranzicije. Pritom nije dokazana nedvoj-
bena povezanost ekspresije NEDD9 s preživljenjem.
Ključne riječi: Plućni tumori; Adenokarcinom; Biopsija, punkcijsko-aspiracijska; Adaptorni proteini, prijenosnici signala; 
 Hrvatska
